logo
logo
logo
logo
Ankit Nigam 2020-10-23
img

According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.

The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.

Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many othersKey Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.Market DriverMarket Barrier The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.Reimbursement scenario and Key Opinion Leader Views Table of ContentsKey InsightsExecutive Summary of NSCLCSWOT Analysis of NSCLCNSCLC: Market Overview at a Glance4.1.

Total Market size of NSCLC in JapanALK-Mutation—Market Size21.1.

Report MethodologyDelveInsight CapabilitiesDisclaimerAbout DelveInsight Request a Webex Demo to get a walk-through of the report:  https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-marketRelated Reports:Non-Small Cell Lung Cancer Epidemiology Forecast to 2030Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020Non-Small Cell Lung Cancer Pipeline Insights, 2020About DelveInsightDelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment.

collect
0
Ankit Nigam 2020-10-12
img

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.

These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.

According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.

The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.

Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.

collect
0
Sonja Clemmons 2019-03-13
img

In an unassuming two-story building at Beijing’s Jingxi Cultural and Creative Park, Chinese mixed reality startup Seengene is working hard to gain ground on Microsoft, Sony, and other international conglomerates that are located in the nearby Zhongguancun Technology Park.

At first glance, it is difficult to see how these pilot versions of children’s games could be of any practical use to businesses, but they are pegged to change the operations of many industries.

“The main reason is that important state funds throw money at unqualified startups, creating market distortions and unrealistic expectations.”

By concentrating their resources on improving the complex technology that allows the virtual and real to interact smoothly and in real-time, as well as prioritizing market-centered applications over far-fetched experimentation, Seengene raised $18 million in a Series A funding round in August 2018, led by Beijing-based venture capital firm Legend Star.

The ability of Seengene’s virtual environment to be fully engaged with physical surroundings is based on powerful 3D positioning software.

Seengene’s MR glasses, called XMAN, look similar to Google Glass, but the Chinese startup has added a whole new dimension to the facial recognition apparatus by integrating 3D visualization and navigation functions that are dependent on mixed reality technology.

collect
0
indian money 2019-01-09
Capital market which is also known as the securities market is a trading market that garners capital from the investors and makes them available to companies and the government for development of projects. The capital market includes the bond market and the stock market among others. The capital market consists of development bank, commercial banks and stock exchanges. Visit indianmoney to read more.
collect
0
Rosalie Lee 2019-08-06

That’s not a secret China has the largest market on the globe.

So everything happening there clearly shows what a situation we have in the global market.

Of course, there are some circumstances that make China’s market differ from the others, but in most cases, it’s the mirror of the world.

But as for the smartphone market, it’s true.

Today, IDC released the second-quarter report of China’s smartphone market in 2019.

According to the report, China’s smartphone shipments in the second quarter were 97.9 million units, down 6.1% year-on-year.

collect
0
nitin jadhav 2021-09-28

The Global Blood Gas and Electrolyte Analyzers Market size is valued to grow at a CAGR of 7.4% during the forecast period.

The study on Blood Gas and Electrolyte Analyzers Market offers historical knowledge and resources for potential use.

The crucial data summed up in this report is reliable and the outcome of extensive research.

It offers analysis of market size & forecasts, growth factors, emerging trends, market opportunities and investment risks across different segments.

This offers an overall understanding of the nature of Blood Gas and Electrolyte Analyzers in terms of both meaning and quantity By Type (Blood Gas Analyzers, Electrolyte Analyzers, Combined Analyzers, Consumables), End User (Central Laboratories, Point-of-Care, Diagnostic Centers), And By Region (North America, Europe, Asia Pacific, Middle East & Africa, and South America) Competitive landscape explores new strategies that various manufacturers are using to increase the competition or retain their market position.

This will help to understand current trends which are rapidly growing.

collect
0
[email protected] rashipande23 2019-12-30

Mantle Cell Lymphoma Treatment MarketData Bridge Market research has recently released expansive research titled “Mantle Cell Lymphoma Treatment Market 2020” guarantees you will remain better informed than your competition.

In this global business document, market overview is given in terms of drivers, restraints, opportunities and challenges where each of this parameter is studied scrupulously.Market Analysis: Global Mantle Cell Lymphoma Treatment MarketMantle cell lymphoma treatment market is growing at a substantial CAGR in the forecast period of 2020-2027.

This rise in the market value can be attributed to the rise in the number of people suffering from mantle cell lymphoma.Key Market Players: The key market players in the mantle cell lymphoma treatment market are F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Amgen Inc, Pfizer Inc, AstraZeneca, Abbott, Eli Lilly and Company, Bayer AG, Novartis AG, Gilead Sciences, Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V, AbbVie Inc, Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, Cipla Inc, Eisai Co., Ltd among others.Get Exclusive sample copy or PDF with (Market Segments, Forecast, Key player’s and TOC) @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-mantle-cell-lymphoma-treatment-marketMarket Outlook: Global Mantle Cell Lymphoma Treatment MarketMantle cell lymphoma is aggressive rare and distinct form of B-cell Non-Hodgkins lymphoma in which abnormal B cell develop in the mantle zone in the lymph nodes and spread to the lymph nodes, bone marrow and other organs.

The patient with mantle cell lymphoma may have swollen lymph nodes, excessive night sweats, weight loss and others.According to the American cancer society, accounting for about 4% of all cancers non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States.

In the year 2019, it estimates that about 74,200 people (41,090 males and 33,110 females) will be diagnosed with NHL and about 19,970 people will die from this cancer (11,510 males and 8,460 females).Market DriversIncrease in approvals for various new drugs by federal agencies  is boosting the market growthRise in investment from government, public & private organizations for the development of novel drugs is acting as catalyst to market growthIncreasing global healthcare expenditure is driving the market growthMarket RestraintsSide effects of these drugs such as neutropenia, anemia, and diarrhea are likely to restrain theHigh cost of chemotherapy and targeted therapy is restraining the market growthPatent expiry of branded drugs is hampering the market growthGlobal Mantle Cell Lymphoma Treatment Market Scope and Market Size:Mantle cell lymphoma treatment market is segmented on the basis of mechanism of action, drugs, route of administration, distribution channel and end user.

The growth among these specific segments will help users analyze niche pockets of growth and strategies to approach the market and determine your core application areas and difference in your target markets.On the basis of mechanism of action, the mantle cell lymphoma treatment market is segmented as Bruton tyrosine kinase inhibitors, alkylating agents, DNA synthesis inhibitors, microtubule inhibitors, monoclonal antibodies and othersOn the basis of drugs, the mantle cell lymphoma treatment market is segmented as rituximab, acalabrutinib, lenalidomide, bortezomib and othersOn the basis of route of administration, the mantle cell lymphoma treatment market is segmented into oral and parenteralOn the basis of distribution channel, the mantle cell lymphoma treatment market is segmented as direct, hospital pharmacy, retail pharmacy and online pharmacyOn the basis of end user, the mantle cell lymphoma treatment market is segmented into hospitals, homecare, specialty clinics and othersGlobal Mantle Cell Lymphoma Treatment Market Country Level AnalysisThe countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific in Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Israel, Egypt, Kuwait, Rest of Middle East and Africa as a part of Middle East and Africa, Argentina, Brazil, Peru and Rest of South America as part of South America.Key Developments in the MarketIn January 2019, BeiGene received the U.S FDA Breakthrough Therapy designation for Zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor to treat adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

collect
0
[email protected] rashipande23 2019-12-30

Service Market for Data Center MarketData Bridge Market research has recently released expansive research titled “Service Market for Data Center Market 2020” guarantees you will remain better informed than your competition.

In this global business document, market overview is given in terms of drivers, restraints, opportunities and challenges where each of this parameter is studied scrupulously.Market Analysis: Global Service Market for Data Center MarketGlobal service market for data center market is registering a healthy CAGR of 14.80% in the forecast period of 2019-2026.

This rise in the market can be attributed to the growing complexities in data center and surging need for reduction of OPEX and CAPEX.Key Market Competitors: Few of the major market competitors currently working in the global service market for data center market are Hewlett Packard Enterprise Development LP, IBM Corporation, Schneider Electric, Inc., Cisco, Dell, FUJITSU, Vertiv Group Corp., Hitachi, Ltd., Equinix, Inc., Huawei Technologies Co., Ltd., Bharat Sanchar Nigam Limited, CtrlS Datacenters Ltd, Netmagic Solutions, Tata Communications, Reliance Industries Limited, Capgemini, HCL Technologies Limited, Sungard Availability Services, CenturyLink, Verizon, KDDI CORPORATION, NTT DATA Corporation, AT Intellectual Property, DuPont de Nemours, Inc. , among others.Get Exclusive sample copy or PDF with (Market Segments, Forecast, Key player’s and TOC) @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-service-market-data-center-marketMarket Definition: Global Service Market for Data Center MarketData centers are networked computers and storage equipment that assist companies to organize process and disseminate big quantities of applications.

Data centers are important assets in day-to-day operations and are a focal point as companies rely on information center services, applications, and data.Market DriversSurging need for reduction of operational costs of data centers is driving the growth of the marketIncreasing investments on data center technology is helping in the growth of the marketGrowing complexities in data centers is flourishing the growth of the marketSurging initiatives from government drives the growth of the marketSegmentation: Global Service Market for Data Center MarketGlobal Service Market for Data Center Market is Segmented By Service Type (Design and consulting, Installation and deployment, Professional, Training and development, Support and maintenance), Tier Type (Tier 1, Tier 2, Tier 3, Tier 4), End-User (Cloud providers, Colocation providers, Enterprises), Data Center Type (Small data centers, Mid-sized data centers, Large data center), Industry (BFSI, IT and telecom, Government and defense, Healthcare, Education, Retail, Energy, Manufacturing, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)Key Developments in the Market:In March 2017, Hewlett Packard Enterprise has launched Pointnext.

It is a newly redefined organization of technology services devoted to assisting businesses accelerate their digital transformations and make the required company results a reality.

By launching this technology HPE has redefined technology services organization.In May 2016, Schneider Electric has launched StruxureWare Data Center Operation v8.0.

collect
0
Adam Martin 2020-11-25

You might not know this but the market dynamics for off market lots is actually very different from the market dynamics for existing homes.

collect
0
[email protected] rashipande23 2019-12-30

Data Bridge Market research has recently released expansive research titled “Carpal Tunnel Syndrome Drug Market 2020” guarantees you will remain better informed than your competition.

In this global business document, market overview is given in terms of drivers, restraints, opportunities and challenges where each of this parameter is studied scrupulously.Market Analysis: Global Carpal Tunnel Syndrome Drug MarketCarpal tunnel syndrome drug market is growing at a steady CAGR in the forecast period of 2020-2027.

The report contains data of the base year 2019 and historic year 2018.

This rise in market value can be attributed to the growing prevalence of carpal tunnel syndrome.Major players in the carpal tunnel syndrome drug market are GlaxoSmithKline plc, ALLERGAN, Pfizer Inc, Johnson & Johnson Services, Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, WOCKHARDT, Mylan N.V, Aurobindo Pharma, Arthrex, Inc, Eisai Co., Ltd, Pressure Profile Systems, Endo Pharmaceuticals Inc, PAVmed Inc, Avadim Health, Inc, Bioness Inc among others.Get Exclusive sample copy or PDF with (Market Segments, Forecast, Key player’s and TOC) @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-carpal-tunnel-syndrome-drug-marketMarket Outlook:: Global Carpal Tunnel Syndrome Drug MarketCarpal tunnel syndrome is also known as median nerve compression neuropathy which is characterized by moderate to severe pain, numbness, tingling or weakness in the upper extremity of the body hand and arm.

The median nerve provides sensation to the thumb and fingers.

Carpal tunnel syndrome can occur in one or both hands.According to the Bureau of Labor and Statistics and the National Institute for Occupational Safety and Health (NIOSH), it is estimated that each year more than eight million people are affected by carpal tunnel syndrome and carpal tunnel surgery is the second most common type of surgery with over 230,000 procedures performed annually.Market DriversIntroduction of innovative therapies is accelerating the market growthRising demand for effective therapies among patients is boosting the market growthRising spending on public health programs is acting as catalyst to market growthIncreasing global healthcare expenditure is driving the market growth  for carpal tunnel syndrome drugMarket RestraintsLack of awareness amongst people about carpal tunnel syndrome is restraining the market growthHigh cost of surgical treatment is hindering the market growth in the forecast periodInadequate reimbursement and lack of availability of skilled professionals are hampering the market growthGlobal Carpal Tunnel Syndrome Drug Market Scope and Market Size:Carpal tunnel syndrome drug market is segmented on the basis of treatment, mechanism of action, drugs, route of administration, distribution channel and end-users.

collect
0
Calvin Bourque 2017-01-13
img

the Market for containers, which are used by developers for packaging applications – "explode" with a variety of startups that want to compete with established suppliers, which increasingly also prioritises this technique.

the Analyst firm 451 Research has come out with one of the first reports to estimate how the market grows.

Right now, sales are quite small: the 2016 turnover of the market of 762 million dollars.

But it will change.

The annual growth rate is expected to be 40 per cent by 2020 – which means that it would then put 2.6 billion dollars.

The report writes 451 Research to the commercial market for containers is only in its infancy.

collect
0
Edward Finlay 2017-01-06

Chinese smartphone upstart Xiaomi Corp. doesn t need to raise additional cash to fund its expansion and plans to take a slow approach to expanding in the U.S., an executive said.

At the consumer electronics expo CES in Las Vegas, Xiaomi s Chief Financial Officer Shou Zi Chew dismissed speculation that the Beijing-based firm could be raising additional funds in response to a challenging year in which Xiaomi has lost smartphone market share to competitors.

I can categorically say there is no reason to go and raise funding, Mr. Chew said in an interview on the sidelines of the show.

Xiaomi, one of China s most valuable startups, with a valuation of $46 billion, soared to the top of China s smartphone market in 2014 by selling sleekly designed smartphones online to cut costs and building buzz with viral marketing.

But in the past two years, it has been overrun by local rivals Oppo, Vivo and Huawei Technologies Co., which used traditional advertising blitzes to win consumers.

Xiaomi s smartphone market share in China—its biggest market—fell to 8.7% in the third quarter of 2016 from 15.9% a year earlier.

collect
0
Rex Canale 2016-09-28
img

The SUV market has been booming for the past few years, and that means the luxury SUV market has also been on the rise.Business has gotten so good that brands that never did SUVs in the past — Jaguar, Lamborghini, Bentley, Maserati — are getting into the game.Consumers have more luxury SUV choices than ever, so choosing the right vehicle can be difficult.

Over the past year, we've sample three good choices: The Lexus RX 350, the Volvo XC90, and the Audi Q7.

So how to chose among them?Read on: View As:

collect
0
Brandon Gaither 2016-09-28
img

The SUV market has been booming for the past few years, and that means the luxury SUV market has also been on the rise.Business has gotten so good that brands that never did SUVs in the past — Jaguar, Lamborghini, Bentley, Maserati — are getting into the game.Consumers have more luxury SUV choices than ever, so choosing the right vehicle can be difficult.

Over the past year, we've sample three good choices: The Lexus RX 350, the Volvo XC90, and the Audi Q7.

So how to chose among them?Read on: View As:

collect
0
InviteReferrals 2021-06-02
img

Undifferentiated Marketing is a market coverage strategy whereby differences within a market are ignoredUndifferentiated marketing is market targeting where you pursue the entire market, rather than specific segments 

collect
0
John Dumlao 2017-01-13
img

the Market for containers, which are used by developers for packaging applications – "explode" with a variety of startups that want to compete with established suppliers, which increasingly also prioritises this technique.

the Analyst firm 451 Research has come out with one of the first reports to estimate how the market grows.

Right now, sales are quite small: the 2016 turnover of the market of 762 million dollars.

But it will change.

The annual growth rate is expected to be 40 per cent by 2020 – which means that it would then put 2.6 billion dollars.

The report writes 451 Research to the commercial market for containers is only in its infancy.

collect
0
Ankit Nigam 2020-10-23
img

According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.

The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.

Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many othersKey Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.Market DriverMarket Barrier The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.Reimbursement scenario and Key Opinion Leader Views Table of ContentsKey InsightsExecutive Summary of NSCLCSWOT Analysis of NSCLCNSCLC: Market Overview at a Glance4.1.

Total Market size of NSCLC in JapanALK-Mutation—Market Size21.1.

Report MethodologyDelveInsight CapabilitiesDisclaimerAbout DelveInsight Request a Webex Demo to get a walk-through of the report:  https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-marketRelated Reports:Non-Small Cell Lung Cancer Epidemiology Forecast to 2030Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020Non-Small Cell Lung Cancer Pipeline Insights, 2020About DelveInsightDelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment.

Sonja Clemmons 2019-03-13
img

In an unassuming two-story building at Beijing’s Jingxi Cultural and Creative Park, Chinese mixed reality startup Seengene is working hard to gain ground on Microsoft, Sony, and other international conglomerates that are located in the nearby Zhongguancun Technology Park.

At first glance, it is difficult to see how these pilot versions of children’s games could be of any practical use to businesses, but they are pegged to change the operations of many industries.

“The main reason is that important state funds throw money at unqualified startups, creating market distortions and unrealistic expectations.”

By concentrating their resources on improving the complex technology that allows the virtual and real to interact smoothly and in real-time, as well as prioritizing market-centered applications over far-fetched experimentation, Seengene raised $18 million in a Series A funding round in August 2018, led by Beijing-based venture capital firm Legend Star.

The ability of Seengene’s virtual environment to be fully engaged with physical surroundings is based on powerful 3D positioning software.

Seengene’s MR glasses, called XMAN, look similar to Google Glass, but the Chinese startup has added a whole new dimension to the facial recognition apparatus by integrating 3D visualization and navigation functions that are dependent on mixed reality technology.

Rosalie Lee 2019-08-06

That’s not a secret China has the largest market on the globe.

So everything happening there clearly shows what a situation we have in the global market.

Of course, there are some circumstances that make China’s market differ from the others, but in most cases, it’s the mirror of the world.

But as for the smartphone market, it’s true.

Today, IDC released the second-quarter report of China’s smartphone market in 2019.

According to the report, China’s smartphone shipments in the second quarter were 97.9 million units, down 6.1% year-on-year.

[email protected] rashipande23 2019-12-30

Mantle Cell Lymphoma Treatment MarketData Bridge Market research has recently released expansive research titled “Mantle Cell Lymphoma Treatment Market 2020” guarantees you will remain better informed than your competition.

In this global business document, market overview is given in terms of drivers, restraints, opportunities and challenges where each of this parameter is studied scrupulously.Market Analysis: Global Mantle Cell Lymphoma Treatment MarketMantle cell lymphoma treatment market is growing at a substantial CAGR in the forecast period of 2020-2027.

This rise in the market value can be attributed to the rise in the number of people suffering from mantle cell lymphoma.Key Market Players: The key market players in the mantle cell lymphoma treatment market are F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Amgen Inc, Pfizer Inc, AstraZeneca, Abbott, Eli Lilly and Company, Bayer AG, Novartis AG, Gilead Sciences, Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V, AbbVie Inc, Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, Cipla Inc, Eisai Co., Ltd among others.Get Exclusive sample copy or PDF with (Market Segments, Forecast, Key player’s and TOC) @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-mantle-cell-lymphoma-treatment-marketMarket Outlook: Global Mantle Cell Lymphoma Treatment MarketMantle cell lymphoma is aggressive rare and distinct form of B-cell Non-Hodgkins lymphoma in which abnormal B cell develop in the mantle zone in the lymph nodes and spread to the lymph nodes, bone marrow and other organs.

The patient with mantle cell lymphoma may have swollen lymph nodes, excessive night sweats, weight loss and others.According to the American cancer society, accounting for about 4% of all cancers non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States.

In the year 2019, it estimates that about 74,200 people (41,090 males and 33,110 females) will be diagnosed with NHL and about 19,970 people will die from this cancer (11,510 males and 8,460 females).Market DriversIncrease in approvals for various new drugs by federal agencies  is boosting the market growthRise in investment from government, public & private organizations for the development of novel drugs is acting as catalyst to market growthIncreasing global healthcare expenditure is driving the market growthMarket RestraintsSide effects of these drugs such as neutropenia, anemia, and diarrhea are likely to restrain theHigh cost of chemotherapy and targeted therapy is restraining the market growthPatent expiry of branded drugs is hampering the market growthGlobal Mantle Cell Lymphoma Treatment Market Scope and Market Size:Mantle cell lymphoma treatment market is segmented on the basis of mechanism of action, drugs, route of administration, distribution channel and end user.

The growth among these specific segments will help users analyze niche pockets of growth and strategies to approach the market and determine your core application areas and difference in your target markets.On the basis of mechanism of action, the mantle cell lymphoma treatment market is segmented as Bruton tyrosine kinase inhibitors, alkylating agents, DNA synthesis inhibitors, microtubule inhibitors, monoclonal antibodies and othersOn the basis of drugs, the mantle cell lymphoma treatment market is segmented as rituximab, acalabrutinib, lenalidomide, bortezomib and othersOn the basis of route of administration, the mantle cell lymphoma treatment market is segmented into oral and parenteralOn the basis of distribution channel, the mantle cell lymphoma treatment market is segmented as direct, hospital pharmacy, retail pharmacy and online pharmacyOn the basis of end user, the mantle cell lymphoma treatment market is segmented into hospitals, homecare, specialty clinics and othersGlobal Mantle Cell Lymphoma Treatment Market Country Level AnalysisThe countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific in Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Israel, Egypt, Kuwait, Rest of Middle East and Africa as a part of Middle East and Africa, Argentina, Brazil, Peru and Rest of South America as part of South America.Key Developments in the MarketIn January 2019, BeiGene received the U.S FDA Breakthrough Therapy designation for Zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor to treat adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Adam Martin 2020-11-25

You might not know this but the market dynamics for off market lots is actually very different from the market dynamics for existing homes.

Calvin Bourque 2017-01-13
img

the Market for containers, which are used by developers for packaging applications – "explode" with a variety of startups that want to compete with established suppliers, which increasingly also prioritises this technique.

the Analyst firm 451 Research has come out with one of the first reports to estimate how the market grows.

Right now, sales are quite small: the 2016 turnover of the market of 762 million dollars.

But it will change.

The annual growth rate is expected to be 40 per cent by 2020 – which means that it would then put 2.6 billion dollars.

The report writes 451 Research to the commercial market for containers is only in its infancy.

Rex Canale 2016-09-28
img

The SUV market has been booming for the past few years, and that means the luxury SUV market has also been on the rise.Business has gotten so good that brands that never did SUVs in the past — Jaguar, Lamborghini, Bentley, Maserati — are getting into the game.Consumers have more luxury SUV choices than ever, so choosing the right vehicle can be difficult.

Over the past year, we've sample three good choices: The Lexus RX 350, the Volvo XC90, and the Audi Q7.

So how to chose among them?Read on: View As:

InviteReferrals 2021-06-02
img

Undifferentiated Marketing is a market coverage strategy whereby differences within a market are ignoredUndifferentiated marketing is market targeting where you pursue the entire market, rather than specific segments 

Ankit Nigam 2020-10-12
img

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.

These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.

According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.

The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.

Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.

indian money 2019-01-09
Capital market which is also known as the securities market is a trading market that garners capital from the investors and makes them available to companies and the government for development of projects. The capital market includes the bond market and the stock market among others. The capital market consists of development bank, commercial banks and stock exchanges. Visit indianmoney to read more.
nitin jadhav 2021-09-28

The Global Blood Gas and Electrolyte Analyzers Market size is valued to grow at a CAGR of 7.4% during the forecast period.

The study on Blood Gas and Electrolyte Analyzers Market offers historical knowledge and resources for potential use.

The crucial data summed up in this report is reliable and the outcome of extensive research.

It offers analysis of market size & forecasts, growth factors, emerging trends, market opportunities and investment risks across different segments.

This offers an overall understanding of the nature of Blood Gas and Electrolyte Analyzers in terms of both meaning and quantity By Type (Blood Gas Analyzers, Electrolyte Analyzers, Combined Analyzers, Consumables), End User (Central Laboratories, Point-of-Care, Diagnostic Centers), And By Region (North America, Europe, Asia Pacific, Middle East & Africa, and South America) Competitive landscape explores new strategies that various manufacturers are using to increase the competition or retain their market position.

This will help to understand current trends which are rapidly growing.

[email protected] rashipande23 2019-12-30

Service Market for Data Center MarketData Bridge Market research has recently released expansive research titled “Service Market for Data Center Market 2020” guarantees you will remain better informed than your competition.

In this global business document, market overview is given in terms of drivers, restraints, opportunities and challenges where each of this parameter is studied scrupulously.Market Analysis: Global Service Market for Data Center MarketGlobal service market for data center market is registering a healthy CAGR of 14.80% in the forecast period of 2019-2026.

This rise in the market can be attributed to the growing complexities in data center and surging need for reduction of OPEX and CAPEX.Key Market Competitors: Few of the major market competitors currently working in the global service market for data center market are Hewlett Packard Enterprise Development LP, IBM Corporation, Schneider Electric, Inc., Cisco, Dell, FUJITSU, Vertiv Group Corp., Hitachi, Ltd., Equinix, Inc., Huawei Technologies Co., Ltd., Bharat Sanchar Nigam Limited, CtrlS Datacenters Ltd, Netmagic Solutions, Tata Communications, Reliance Industries Limited, Capgemini, HCL Technologies Limited, Sungard Availability Services, CenturyLink, Verizon, KDDI CORPORATION, NTT DATA Corporation, AT Intellectual Property, DuPont de Nemours, Inc. , among others.Get Exclusive sample copy or PDF with (Market Segments, Forecast, Key player’s and TOC) @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-service-market-data-center-marketMarket Definition: Global Service Market for Data Center MarketData centers are networked computers and storage equipment that assist companies to organize process and disseminate big quantities of applications.

Data centers are important assets in day-to-day operations and are a focal point as companies rely on information center services, applications, and data.Market DriversSurging need for reduction of operational costs of data centers is driving the growth of the marketIncreasing investments on data center technology is helping in the growth of the marketGrowing complexities in data centers is flourishing the growth of the marketSurging initiatives from government drives the growth of the marketSegmentation: Global Service Market for Data Center MarketGlobal Service Market for Data Center Market is Segmented By Service Type (Design and consulting, Installation and deployment, Professional, Training and development, Support and maintenance), Tier Type (Tier 1, Tier 2, Tier 3, Tier 4), End-User (Cloud providers, Colocation providers, Enterprises), Data Center Type (Small data centers, Mid-sized data centers, Large data center), Industry (BFSI, IT and telecom, Government and defense, Healthcare, Education, Retail, Energy, Manufacturing, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)Key Developments in the Market:In March 2017, Hewlett Packard Enterprise has launched Pointnext.

It is a newly redefined organization of technology services devoted to assisting businesses accelerate their digital transformations and make the required company results a reality.

By launching this technology HPE has redefined technology services organization.In May 2016, Schneider Electric has launched StruxureWare Data Center Operation v8.0.

[email protected] rashipande23 2019-12-30

Data Bridge Market research has recently released expansive research titled “Carpal Tunnel Syndrome Drug Market 2020” guarantees you will remain better informed than your competition.

In this global business document, market overview is given in terms of drivers, restraints, opportunities and challenges where each of this parameter is studied scrupulously.Market Analysis: Global Carpal Tunnel Syndrome Drug MarketCarpal tunnel syndrome drug market is growing at a steady CAGR in the forecast period of 2020-2027.

The report contains data of the base year 2019 and historic year 2018.

This rise in market value can be attributed to the growing prevalence of carpal tunnel syndrome.Major players in the carpal tunnel syndrome drug market are GlaxoSmithKline plc, ALLERGAN, Pfizer Inc, Johnson & Johnson Services, Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, WOCKHARDT, Mylan N.V, Aurobindo Pharma, Arthrex, Inc, Eisai Co., Ltd, Pressure Profile Systems, Endo Pharmaceuticals Inc, PAVmed Inc, Avadim Health, Inc, Bioness Inc among others.Get Exclusive sample copy or PDF with (Market Segments, Forecast, Key player’s and TOC) @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-carpal-tunnel-syndrome-drug-marketMarket Outlook:: Global Carpal Tunnel Syndrome Drug MarketCarpal tunnel syndrome is also known as median nerve compression neuropathy which is characterized by moderate to severe pain, numbness, tingling or weakness in the upper extremity of the body hand and arm.

The median nerve provides sensation to the thumb and fingers.

Carpal tunnel syndrome can occur in one or both hands.According to the Bureau of Labor and Statistics and the National Institute for Occupational Safety and Health (NIOSH), it is estimated that each year more than eight million people are affected by carpal tunnel syndrome and carpal tunnel surgery is the second most common type of surgery with over 230,000 procedures performed annually.Market DriversIntroduction of innovative therapies is accelerating the market growthRising demand for effective therapies among patients is boosting the market growthRising spending on public health programs is acting as catalyst to market growthIncreasing global healthcare expenditure is driving the market growth  for carpal tunnel syndrome drugMarket RestraintsLack of awareness amongst people about carpal tunnel syndrome is restraining the market growthHigh cost of surgical treatment is hindering the market growth in the forecast periodInadequate reimbursement and lack of availability of skilled professionals are hampering the market growthGlobal Carpal Tunnel Syndrome Drug Market Scope and Market Size:Carpal tunnel syndrome drug market is segmented on the basis of treatment, mechanism of action, drugs, route of administration, distribution channel and end-users.

Edward Finlay 2017-01-06

Chinese smartphone upstart Xiaomi Corp. doesn t need to raise additional cash to fund its expansion and plans to take a slow approach to expanding in the U.S., an executive said.

At the consumer electronics expo CES in Las Vegas, Xiaomi s Chief Financial Officer Shou Zi Chew dismissed speculation that the Beijing-based firm could be raising additional funds in response to a challenging year in which Xiaomi has lost smartphone market share to competitors.

I can categorically say there is no reason to go and raise funding, Mr. Chew said in an interview on the sidelines of the show.

Xiaomi, one of China s most valuable startups, with a valuation of $46 billion, soared to the top of China s smartphone market in 2014 by selling sleekly designed smartphones online to cut costs and building buzz with viral marketing.

But in the past two years, it has been overrun by local rivals Oppo, Vivo and Huawei Technologies Co., which used traditional advertising blitzes to win consumers.

Xiaomi s smartphone market share in China—its biggest market—fell to 8.7% in the third quarter of 2016 from 15.9% a year earlier.

Brandon Gaither 2016-09-28
img

The SUV market has been booming for the past few years, and that means the luxury SUV market has also been on the rise.Business has gotten so good that brands that never did SUVs in the past — Jaguar, Lamborghini, Bentley, Maserati — are getting into the game.Consumers have more luxury SUV choices than ever, so choosing the right vehicle can be difficult.

Over the past year, we've sample three good choices: The Lexus RX 350, the Volvo XC90, and the Audi Q7.

So how to chose among them?Read on: View As:

John Dumlao 2017-01-13
img

the Market for containers, which are used by developers for packaging applications – "explode" with a variety of startups that want to compete with established suppliers, which increasingly also prioritises this technique.

the Analyst firm 451 Research has come out with one of the first reports to estimate how the market grows.

Right now, sales are quite small: the 2016 turnover of the market of 762 million dollars.

But it will change.

The annual growth rate is expected to be 40 per cent by 2020 – which means that it would then put 2.6 billion dollars.

The report writes 451 Research to the commercial market for containers is only in its infancy.